Stifel Reiterates Hold Rating on BioMarin Pharmaceutical Inc. (BMRN)

Market Context

BioMarin Pharmaceutical Inc. operates in the Healthcare sector. The stock currently trades at $54.05 with a market capitalization of $10.2B. The stock has gained 10.7% over the past 52 weeks.

Analyst coverage from Stifel provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for BioMarin Pharmaceutical Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for BioMarin Pharmaceutical Inc.

Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 03, 2026	Stifel	Hold	N/A
Oct 21, 2026	Morgan Stanley	Overweight	N/A
Oct 20, 2026	JP Morgan	Overweight	N/A
Oct 20, 2026	Cantor Fitzgerald	Overweight	N/A
Oct 14, 2026	Barclays	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View BMRN Stock Page